- Home
- MRCC vs DTIL Comparison
MRCC vs DTIL Comparison
Compare MRCC & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | DTIL |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 115.5M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MRCC | DTIL |
|---|---|---|
| Price | $6.16 | $4.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $47.00 |
| AVG Volume (30 Days) | 104.7K | ★ 202.5K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 11.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.86 | $3.61 |
| 52 Week High | $8.85 | $8.82 |
Technical Indicators
Market Signals| Indicator | MRCC | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 30.41 |
| Support Level | $6.20 | $4.17 |
| Resistance Level | $6.80 | $5.04 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 27.18 | 3.88 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.